{"id":952415,"date":"2026-04-17T06:03:22","date_gmt":"2026-04-17T10:03:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/"},"modified":"2026-04-17T06:03:22","modified_gmt":"2026-04-17T10:03:22","slug":"bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/","title":{"rendered":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bruker Launches MyGenius PRO<sup>\u00ae<\/sup> High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026<\/b><\/p>\n<p>MUNICH&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAt <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.escmid.org&amp;esheet=54516456&amp;newsitemid=20260417698008&amp;lan=en-US&amp;anchor=ESCMID+Global+2026&amp;index=1&amp;md5=7f4e58c48900b4b261f7aef55ca7b91d\">ESCMID Global 2026<\/a>, the Bruker Microbiology &amp; Infection Diagnostics division (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54516456&amp;newsitemid=20260417698008&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=2&amp;md5=3bf4468d6c1ce944b9af533805ddf03d\">Bruker Corporation<\/a>, Nasdaq: BRKR) announces the European launch of <b>MyGenius PRO<sup>\u00ae<\/sup><\/b>, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput <b>BeGenius<sup>\u00ae<\/sup><\/b>system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO<sup>\u00ae<\/sup> automates the entire workflow &#8211; from patient sample to diagnostic result &#8211; enhancing laboratory efficiency and supporting higher-throughput volume testing needs.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260417698008\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260417698008\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 429px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg\" alt=\"MyGenius PRO\u00ae installed at a leading European transplant center supporting routine infectious disease testing\" \/><\/p>\n<p style=\"font-size:85%\">MyGenius PRO\u00ae installed at a leading European transplant center supporting routine infectious disease testing<\/p>\n<\/div>\n<p>\nAt launch, the MyGenius PRO<sup>\u00ae<\/sup> IVDR menu will include assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.<\/p>\n<p>\nThe MyGenius PRO<sup>\u00ae <\/sup>platform was developed in a collaboration between ELITechGroup, a Bruker company, and Hitachi High Tech-Corporation (Hitachi High-Tech), combining complementary expertise in molecular assays, automation and engineering. Hitachi High-Tech will introduce the platform under the tradename <b>LABOSPECT GA-5 <\/b>in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.<\/p>\n<p>\nDuring a recent interview, Dr. Pierangelo Clerici, President of AMCLI (Italian Association of Clinical Microbiologists), emphasized the importance of high throughput in microbiology laboratories: \u201cTimely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations.\u201d<\/p>\n<p>\nThe launch of MyGenius PRO<sup>\u00ae<\/sup> marks a new chapter in Bruker\u2019s Microbiology &amp; Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius<sup>\u00ae<\/sup>, BeGenius<sup>\u00ae<\/sup>, a rapidly growing CE-IVD assay menu, and novel LiquidArray<sup>\u00ae<\/sup> assays for advanced multiplexing and more affordable syndromic panel testing.<\/p>\n<p><b>About Bruker Corporation \u2013 Leader of the Post-Genomic Era <\/b>(Nasdaq: BRKR)<\/p>\n<p>\nBruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker\u2019s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54516456&amp;newsitemid=20260417698008&amp;lan=en-US&amp;anchor=www.bruker.com&amp;index=3&amp;md5=e1e8edb910edb7b806763221859888f4\">www.bruker.com<\/a>.<\/p>\n<p><b>About Hitachi High-Tech<\/b><\/p>\n<p>\nHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including manufacture and sales of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provide high value-added solutions in industrial fields such as mobility, environment and energy, etc.<\/p>\n<p>\nFor further information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hitachi-hightech.com%2Fglobal%2Fen%2F&amp;esheet=54516456&amp;newsitemid=20260417698008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.hitachi-hightech.com%2Fglobal%2Fen%2F&amp;index=4&amp;md5=90a68a61f2e2a692abe010384ea86726\">https:\/\/www.hitachi-hightech.com\/global\/en\/<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260417698008r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260417698008\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260417698008\/en\/<\/a><\/span><\/p>\n<p><b>Trade Press &amp; Customer Contact:<br \/>\n<\/b><br \/>Alessandro Abramo<br \/>\n<br \/>Director Marketing &amp; Product Management<br \/>\n<br \/>Bruker Microbiology &amp; Infection Diagnostics Division<br \/>\n<br \/>T: +39-348-360-9058<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:alessandro.abramo@bruker.com\">alessandro.abramo@bruker.com<\/a><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Joe Kostka<br \/>\n<br \/>Director, Investor Relations &amp; Corporate Development<br \/>\n<br \/>Bruker Corporation<br \/>\n<br \/>T: +1 (978) 313-5800<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:Investor.Relations@bruker.com\">Investor.Relations@bruker.com<\/a><\/p>\n<p>\n\u00a0<\/p>\n<p><b>KEYWORDS:<\/b> Germany Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Research Infectious Diseases Semiconductor Clinical Trials Biotechnology Health Pharmaceutical Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/3\/MyGenius_PRO.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">MyGenius PRO\u00ae installed at a leading European transplant center supporting routine infectious disease testing<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776831\/3\/MyGenius_PRO_Assays.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">The assays for CMV, EBV, and BKV launched with the MyGenius PRO\u00ae under IVDR<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/772973\/3\/Bruker_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 MUNICH&#8211;(BUSINESS WIRE)&#8211; At ESCMID Global 2026, the Bruker Microbiology &amp; Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO\u00ae, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius\u00aesystem, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO\u00ae automates the entire workflow &#8211; from patient sample to diagnostic result &#8211; enhancing laboratory efficiency and supporting higher-throughput volume testing needs. This press release features multimedia. View the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952415","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 MUNICH&#8211;(BUSINESS WIRE)&#8211; At ESCMID Global 2026, the Bruker Microbiology &amp; Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO\u00ae, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius\u00aesystem, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO\u00ae automates the entire workflow &#8211; from patient sample to diagnostic result &#8211; enhancing laboratory efficiency and supporting higher-throughput volume testing needs. This press release features multimedia. View the &hellip; Continue reading &quot;Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T10:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026\",\"datePublished\":\"2026-04-17T10:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/\"},\"wordCount\":710,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260417698008\\\/en\\\/2776830\\\/4\\\/MyGenius_PRO.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/\",\"name\":\"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260417698008\\\/en\\\/2776830\\\/4\\\/MyGenius_PRO.jpg\",\"datePublished\":\"2026-04-17T10:03:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260417698008\\\/en\\\/2776830\\\/4\\\/MyGenius_PRO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260417698008\\\/en\\\/2776830\\\/4\\\/MyGenius_PRO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/","og_locale":"en_US","og_type":"article","og_title":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk","og_description":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 MUNICH&#8211;(BUSINESS WIRE)&#8211; At ESCMID Global 2026, the Bruker Microbiology &amp; Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO\u00ae, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius\u00aesystem, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO\u00ae automates the entire workflow &#8211; from patient sample to diagnostic result &#8211; enhancing laboratory efficiency and supporting higher-throughput volume testing needs. This press release features multimedia. View the &hellip; Continue reading \"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T10:03:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026","datePublished":"2026-04-17T10:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/"},"wordCount":710,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/","name":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg","datePublished":"2026-04-17T10:03:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260417698008\/en\/2776830\/4\/MyGenius_PRO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bruker-launches-mygenius-pro-high-throughput-sample-to-answer-molecular-diagnostics-system-at-escmid-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bruker Launches MyGenius PRO\u00ae High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952415"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952415\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}